Navigation Links
Warner Chilcott Announces Secondary Equity Offering
Date:11/13/2009

ARDEE, Ireland, Nov. 13 /PRNewswire-FirstCall/ -- Warner Chilcott plc (Nasdaq: WCRX) today announced a 20,000,000 share secondary offering of its ordinary shares by certain selling shareholders. The selling shareholders include funds affiliated with Bain Capital Partners, DLJ Merchant Banking, J.P. Morgan Partners (advised by CCMP Capital) and Thomas H. Lee Partners, L.P., certain other institutional investors and members of the Company's senior management. The offering is being conducted as a public offering pursuant to an effective shelf registration statement under the Securities Act of 1933. The Company will not receive any proceeds from the sale of the shares but will pay the expenses of the offering.

The offering is being made through an underwriting syndicate, led by Goldman, Sachs & Co., Morgan Stanley, Credit Suisse and J.P. Morgan. The co-managers of the offering are BofA Merrill Lynch, Barclays Capital, Citi, Deutsche Bank Securities and UBS Investment Bank.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be a sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering is being made by means of a prospectus supplement and the accompanying prospectus only. Copies of the prospectus supplement and accompanying prospectus can be obtained by contacting Goldman, Sachs & Co., at 85 Broad Street, New York, NY 10004, Attention: Prospectus Department, by telephone at 1-866-471-2526 or by emailing Prospectus-ny@ny.email.gs.com; Morgan Stanley & Co. Incorporated, at 180 Varick Street, 2nd Floor, New York, NY 10014, Attention: Prospectus Department, by telephone at 1-866-718-1649 or by emailing prospectus@morganstanley.com; Credit Suisse Securities (USA) LLC, at One Madison Avenue, New York, NY 10010, Attention: Credit Suisse Prospectus Department or by telephone at 1-800-221-1037; or J.P. Morgan Securities Inc., at 4 Chase Metrotech Center, Floor 04, Brooklyn, NY 11245-0001, Attention: J.P. Morgan Securities Inc. or by telephone at 1-718-242-8002.

The Company

Warner Chilcott is a leading specialty pharmaceutical company currently focused on the gastroenterology, women's healthcare, dermatology and urology segments of the U.S. and Western European pharmaceuticals markets. The Company is a fully integrated company with internal resources dedicated to the development, manufacturing and promotion of its products. WCRX-F

Forward Looking Statements

This press release contains forward-looking statements, including statements concerning our operations, our economic performance and financial condition, and our business plans and growth strategy and product development efforts. These statements constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words "may," "might," "will," "should," "estimate," "project," "plan," "anticipate," "expect," "intend," "outlook," "believe" and other similar expressions are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties. The following represent some, but not necessarily all, of the factors that could cause actual results to differ from historical results or those anticipated or predicted by our forward-looking statements: our substantial indebtedness; competitive factors in the industry in which we operate (including the approval and introduction of generic or branded products that compete with our products); our ability to protect our intellectual property; a delay in qualifying our manufacturing facility to produce our products or production or regulatory problems with either third party manufacturers upon whom we may rely for some of our products or our own manufacturing facilities; pricing pressures from reimbursement policies of private managed care organizations and other third party payors, government sponsored health systems, the continued consolidation of the distribution network through which we sell our products, including wholesale drug distributors and the growth of large retail drug store chains; the loss of key senior management or scientific staff; adverse outcomes in our outstanding litigation or an increase in the number of litigation matters to which we are subject; government regulation affecting the development, manufacture, marketing and sale of pharmaceutical products, including our ability and the ability of companies with whom we do business to obtain necessary regulatory approvals; our ability to manage the growth of our business by successfully identifying, developing, acquiring or licensing new products at favorable prices and marketing such new products; our ability to obtain regulatory approval and customer acceptance of new products, and continued customer acceptance of our existing products; changes in tax laws or interpretations that could increase our consolidated tax liabilities; the other risks identified in our periodic filings including our Annual Report on Form 10-K for the year ended December 31, 2008, as amended, and our Current Report on Form 8-K filed on November 2, 2009; and other risks detailed from time-to-time in our public filings, financial statements and other investor communications.

We caution you that the foregoing list of important factors is not exclusive. In addition, in light of these risks and uncertainties, the matters referred to in our forward-looking statements may not occur. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as may be required by law.

SOURCE Warner Chilcott plc


'/>"/>
SOURCE Warner Chilcott plc
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Warner Chilcott Completes Acquisition of P&Gs Global Branded Prescription Pharmaceuticals Business
2. Dr. Mahdi B. Fawzi Joins Warner Chilcott as President, Global Research and Development
3. Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent
4. Tianyin Pharmaceutical co., Inc. Announces Record First Quarter 2010 Financial Results
5. Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months
6. Kun Run Biotechnology, Inc. Announces Third Quarter 2009 Results
7. Misonix Announces New Distribution Agreement for Saudi Arabia and Other Middle Eastern Countries
8. Milestone Scientific Announces Third Quarter 2009 Results
9. EF Johnson Technologies Announces Third Quarter Results
10. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
11. LifeVantage Announces Unaudited First Quarter Fiscal 2010 Financial and Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... -- HealthMine surveys with 9,250 insured consumers fielded from February ... want help from their plans in five key areas: ... 2) help closing gaps in care, 3) better digital ... relevant, real-time guidance. Meeting these needs is essential to ... A Reason to Stay Engaged in Health ...
(Date:3/23/2017)... Mar 23, 2017 Research and Markets has ... Trends - Industry Forecast to 2025" report to their offering. ... The Global ... 6.9% over the next decade to reach approximately $3.5 billion by ... forecasts for all the given segments on global as well as ...
(Date:3/23/2017)... March 23, 2017 ... created through extensive primary research (inputs from industry ... aims to present the analysis of global heart ... (Replacement and Repair); Replacement Procedure By Technique (Mechanical, ... Technique (Surgical Devices, Balloon Valvuloplasty, Transcatheter Mitral Valve ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... ... soil, dredged material, and hazardous and non-hazardous materials announced today the acquisition of ... This acquisition will add four additional processing facilities and a vast array of ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... third world countries to hospitals in the United States, it’s a threat that ... the current obstacles facing infection prevention and offers strategies for the healthcare community ...
(Date:3/24/2017)... ... March 24, 2017 , ... According to a new study by ... it does not obey the rules Congress has directed the CBO to follow. The ... GOP reform would restore. Yet, it estimates a reduction in employer-based coverage due to ...
(Date:3/24/2017)... Lake Orion, MI (PRWEB) , ... March 24, ... ... providing insurance assistance, financial planning, and related services to families and business owners ... charity initiative aimed at feeding regional families struggling with financial difficulties. , The ...
(Date:3/24/2017)... ... March 24, 2017 , ... As ... to create a communications platform that positions them as the go-to thought leader ... reinvented their online publication as an always-on, always-fresh news, views and advocacy engine, ...
Breaking Medicine News(10 mins):